Hugan tablet sales temporarily halted

|By:, SA News Editor

The China Food and Drug Administration halts the sale of Tianyin Pharmaceuticals' (TPI +3.1%) liver drug Hugan as it performs due diligence on its price and GMP before awarding the firm the right to sell the product in Zhejiang province. The agency's action is a customary part of its regulatory process.

The product contributes ~$600K in annual sales.

The company expects the examination to be over in April and sales will recommence.